Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Cyclin L1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA584358
Description
Immunogen sequence: SKPSSPREVK AEEKSPISIN VKTVKKEPED RQQASKSPYN GVRKDSKRSR NSRS.
FUS/TLS was originally described as fused in Sarcoma is actually related to a number of different cellular processes and correlated to several diseases. FUS binds DNA as a single or double strand, and acts as a site for transcription factors to recognize. Since FUS is well-documented to be involved in liposarcoma, lipoma and leukaemia, it is believed that when its normal housekeeping functions related to transcription are disrupted, normal cells become cancerous. Interestingly, FUS is also associated with the fatal neuron disorder amyotrophic lateral sclerosis; interruption of its normal RNA-binding functions leads to incorrect cellular localization and leads to pathologies of the neuron. Thus, FUS regulation of cellular functions is a critical component of maintenance of healthy cells.
Specifications
Cyclin L1 | |
Polyclonal | |
Unconjugated | |
Ccnl1 | |
2610030E23Rik; ANIA6A; ania-6a; AU018493; BM-001; Ccn1; Ccnl; CCNL1; Cyclin Ania-6a; cyclin L ania-6a; cyclin L gamma; cyclin L1; cyclin-L; Cyclin-L1; LOW QUALITY PROTEIN: cyclin-L1; PRO1073; UNQ530/PRO1073 | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
57018 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunocytochemistry, Immunofluorescence | |
0.3 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q9UK58 | |
Ccnl1 | |
Recombinant protein corresponding to Human CCNL1. Recombinant protein control fragment (Product #RP-105087). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction